ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced results from a multi-site clinical validation study of its TAEUS Liver device.
The study included 64 patients across the US and Canada, including an external validation site in London, Ontario.
Results showed a correlation of 0.90 with MRI-PDFF and diagnostic accuracy between 0.95 and 0.99 at key thresholds. Mean error was about 3%.
The portable point-of-care system costs under $200 per scan, compared to typical MRI costs.
CEO Alexander Tokman: "TAEUS Liver delivers MRI-like liver fat quantification at the point of patient care."
The company also disclosed a Nasdaq notice for non-compliance with minimum equity requirements and is exploring strategic alternatives.
